INNOVATIVE PERSPECTIVES OF THE UTILIZATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR MANAGING OBESE POLYCYSTIC OVARY SYNDROME (PCOS) WOMEN & TREATMENT OFNON PCOS OBESE INFERTILE WOMEN FORIMPROV ING PREGNANCY & LIVE BIRTH RATES - A SHORT COMMUN

Having comprehensively reviewed earlier the Polycystic ovary syndrome (PCOS) classification, methodologies for weight reduction inclusive of targeting brown adipose tissue (BAT) in PCOS and in routine obesityinclusive of i) Orlistat (Xenical) to ii)Combinational Agents -a)QsymiaTM (phentermine hydrochloride/ delayed release topiramate beads (TPM), b) Contrave(Bupropion/ Naltrexone)/just topiramate which wasfollowed by GLP1R Agonists -Liraglutide3mg. Nonetheless, till 2019 maximum pharmacotherapy did not yield sustenance of weight reduction and did notprove to be efficacious over 1-5kg reduction for greater than 3-6mths. The only drug that illustrated some promise were believed to be thylakoids. Therefore, a single drug in which agonism for the receptors of glucagon, glucagon like peptide1 (GLP1), glucose dependent insulinotropic polypeptide (GIP) was combined in view of mechanistic modes of bariatric surgery (BS) was posited to be through central nervous system(CNS), and certain other GIT hormones for instance GLP1, ghrelin and PYY. Nonetheless, we did not utilize GLP1RAs in women with PCOS, due to expenses, parenteral use, accessiblity nevertheless, we reviewed Obesity and Heart failure with preserved ejection fraction (HFpEF) glucagon like peptide 1(GLP-1)-1 receptor agonist(GLP-1RA), inclusive of long acting GLP-1RA’s for instance liraglutide and, oral semaglutide gets done/day, whereas dulaglutide, exenatideextended release, subcutaneous(s/c) semaglutidedelivery with gets done once weekly. Here we present, the manner GLP1RAs, especially, the latest GLP-1RA’s might prove to be efficacious in obese PCOS women in reference to weight reduction prior to embarking on pregnancy for improving pregnancy rate(PR) & live birth rates(LBR), however greater work is required regarding newer GLP1Ras, since it has been observed newer GLP1Rpossess definitive greater weight reduction efficacy in contrast to liraglutide and other first generationGLP1R prior to undergoing pregnancy, would conclusively aid in escalating the PR and LBR, but needs studying in PCOS effects of semaglutide, Tirzepatide(GLP1+ GIP)) combo as only restrictedly studied.